ReviewJournal of cardiovascular development and disease2023
Effects of Lipid Lowering Therapies on Vulnerable Plaque Features: An Updated Narrative Review of the Literature.
Review in Journal of cardiovascular development and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 14 citations in OpenAlex.
- Coronary atherosclerotic plaque intervention with Tongxinluo capsule (TXL-CAP): a multicenter, randomized, double-blind and placebo-controlled study.Signal transduction and targeted therapy · 2026Trial
- Clinical observation of renal artery stenosis treated with PCSK9 inhibitor.BMC cardiovascular disorders · 2026Observational
- Coronary artery anomalies: contemporary approaches to risk stratification and management.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- PCSK9 inhibitors conquer primary prevention: the VESALIUS-CV study.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Knowledge, Attitudes, and Practices Regarding PCSK9 Inhibitors Among Healthcare Professionals: Exploring Behavioral Pathways and the Intermediary Role of Attitude.Journal of multidisciplinary healthcare · 2026Article
- Effects of different statin-based lipid-lowering therapies on stabilization and regression of carotid plaque: a randomized open-label trial.Frontiers in pharmacology · 2026Article
- Unraveling the temporal sequence of coronary atherosclerosis modification with lipid-lowering therapies through intravascular imaging: a narrative review.Frontiers in cardiovascular medicine · 2026Review
- Atrial fibrillation and acute myocardial infarction: a Two-Way relationship.Frontiers in cardiovascular medicine · 2026Review
- Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction.European heart journal. Cardiovascular pharmacotherapy · 2025Article
- Reducing the risk of heart attack: the key role of lipid profiling and atherosclerosis imaging.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Seeking and treating inflammation in ischaemic heart disease: are we ready?European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- The role of functional assessment in the management of ischaemic heart disease.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Long-term outcomes according to absolute value vs. percentage reduction in low-density lipoprotein cholesterol levels after acute myocardial infarction.Frontiers in cardiovascular medicine · 2025Article
- Independent role of atherosclerotic plaque composition and extension in predicting the risk of cardiac events: a CLIMA substudy.The international journal of cardiovascular imaging · 2024Observational
- Innovations in Intracoronary Imaging: Present Clinical Practices and Future Outlooks.Journal of clinical medicine · 2024Review
- A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients-A Review PART II-Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory.Journal of clinical medicine · 2024Review
- Wildfire smoke exposure and cardiovascular disease-should statins be recommended to prevent cardiovascular events?Frontiers in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical evidence on the efficacy of lipid lowering therapy in patients with coronary artery disease (CAD) is unequivocally established. However, the effects of these therapies on plaque composition and stability are less clear. The use of intracoronary imaging (ICI) technologies has emerged as a complement to conventional angiography to further characterize plaque morphology and detect high-risk plaque features related to cardiovascular events. Along with clinical outcomes studies, parallel imaging trials employing serial evaluations with intravascular ultrasound (IVUS) have shown that pharmacological treatment has the capacity to either slow disease progression or promote plaque regression, depending on the degree of lipid lowering achieved. Subsequently, the introduction of high-intensity lipid lowering therapy led to much lower levels of low-density lipoprotein cholesterol (LDL-C) levels than achieved in the past, resulting in greater clinical benefit. However, the degree of atheroma regression showed in concomitant imaging trials appeared more modest as compared to the magnitude of clinical benefit accrued from high-intensity statin therapy. Recently, new randomized trials have investigated the additional effects of achieving very low levels of LDL-C on high-risk plaque features-such as fibrous cap thickness and large lipid accumulation-beyond its size. This paper provides an overview of the currently available evidence of the effects of moderate to high-intensity lipid lowering therapy on high-risk plaque features as assessed by different ICI modalities, reviews data supporting the use of these trials, and analyse the future perspectives in this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.